Drug Profile
Research programme: diabetes therapy - Sanofi/Joslin Diabetes Center
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Joslin Diabetes Center; Sanofi
- Class Insulins; Small molecules
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Diabetes mellitus
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Diabetes-mellitus in France
- 16 Jul 2016 No recent reports of development identified for research development in Diabetes-mellitus in USA
- 09 Jun 2016 Joslin Diabetes Center extends collaboration with Sanofi, for the development of novel treatments for diabetes